Safety of vitamin D3 in adults with multiple sclerosis

American Journal of Clinical Nutrition

Volumn 86, Issue 3, 2007, Pages 645-651

  Kimball, Samantha M ^a,b   Ursell, Melanie R ^c   O'Connor, Paul ^c   Vieth, Reinhold ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

25(OH)D; 25 hydroxyvitamin D; Multiple sclerosis; Safety; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL; CREATININE; ELECTROLYTE; GADOLINIUM; LIVER ENZYME; PARATHYROID HORMONE; PROTEIN; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE INCREASE; ELECTROLYTE BLOOD LEVEL; FEMALE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MALE; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; STATISTICS; STUDENT T TEST; URINALYSIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; ENZYMOLOGY; HYPOCALCEMIA; LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; REFERENCE VALUE; RISK FACTOR; SAFETY; TIME; TREATMENT OUTCOME; URINE; VITAMIN D DEFICIENCY;

ADULT; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; CREATININE; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOCALCEMIA; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PARATHYROID HORMONE; REFERENCE VALUES; RISK FACTORS; SAFETY; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 34548715246     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.3.645     Document Type: Article

References (48)

1. Food Standards Agency. Safe upper levels for vitamins and minerals. London, United Kingdom: UK Foods Standards Agency, 2003.
2. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 2006;136:1117-22.
3. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997.
4. Recommended dietary allowances. Washington, DC: National Academy Press, 1989.
5. Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001;55:1091-7.
6. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-10.
7. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
8. Vieth R, Cole DE. Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med 2005;353:634-5.
9. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
10. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
11. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13-9.
12. May E, Asadullah K, Zugel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy 2004;3:377-93.
13. Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol 1998;160:209-18.
14. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995;15:5789-99.
15. Cantorna MT, Woodward WD, Hayes CE, Deluca HF. 1,25-dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998;160:5314-9.
16. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-4.
17. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
18. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol 1995;61:151-60.
19. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-9.
20. Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276-7.
21. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;48:271-2.
22. Grimes DS. Are statins analogues of vitamin D? Lancet 2006;368:83-6.
23. Munro I. Derivation of tolerable upper intake levels of nutrients. Am J Clin Nutr 2001;74:865-7.
24. Vieth R, Kimball S. Vitamin D in congestive heart failure. Am J Clin Nutr 2006;83:731-2.
25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
26. 3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-94.
27. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004;3:8.
28. Trang H, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998;68:854-48.
29. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-56.
30. Vieth R. The pharmacology of vitamin D, including fortification strategies. In: Feldman D, Glorieux F, Pike JW, eds. Vitamin D. New York, NY: Elsevier, 2005:995-1015.
31. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
32. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004;164:885-91.
33. Rizzoli R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: effects of clodronate therapy. Bone 1994;15:193-8.
34. Pettifor JM, Bikle DD, Cavaleros M, Zachen D, Kamdar MC, Ross FP. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med 1995;122:511-3.
35. Vieth R, Pinto T, Reen BS, Wong MM. Vitamin D poisoning by table sugar. Lancet 2002;359:672.
36. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6.
37. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004;229:1136-42.
38. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986;21:193-200.
39. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003;134:128-32.
40. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) forrelapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-6.
41. Vieth R, Milojevic S, Peltekova V. Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol. J Nutr 2000;130:578-84.
42. Balabanova S, Richter HP, Antoniadis G, et al. 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin Wochenschr 1984;62:1086-90.
43. Vieth R, McCarten K, Norwich KH. Role of 25-hydroxyvitamin D3 dose in determining rat 1,25-dihydroxyvitamin D3 production. Am J Physiol 1990;258:E780-9.
44. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888-94.
45. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
46. Riaz S, Malcangio M, Miller M, Tomlinson DR. A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 1999;42:1308-13.
47. Kalueff AV, Eremin KO, Tuohimaa P. Mechanisms of neuroprotective action of vitamin d(3). Biochemistry (Mosc) 2004;69:738-41.
48. Hathcock JN, Shao A, Vieth R, Heaney R. A risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.